Edwige Beng-Louka | Senior scientist
Novartis Pharma AG

Festival of Biologics Day 3 @ 12:10

Profiling and characterizing O-glycosylation in the hinge region of immunoglobulin A by bottom-up mass spectrometry.

IgA Nephropathy is an autoimmune disease which has been recognized as an important cause of chronic kidney disease and end stage kidney failure. This condition is marked by the production of aberrantly glycosylated IgA1 by memory B and plasma cells. Therefore, characterizing the glycosylation pattern of IgA1 is crucial.

IgA1 undergoes post-translational modification through O-glycosylation at six serine and threonine residues in the hinge region. This results in a wide heterogeneity of O-glycoforms, which can be categorized into two groups: galactose-deficient (where at least one GalNAc residue is not linked to a Galactose residue) and non-galactose-deficient.

An automated profiling workflow is employed to classify the O-glycosylation pattern of IgA1 using LC-MS after tryptic digestion. Additionally, an in-depth characterization method has been developed to pinpoint the galactose-deficient sites. This method combines specific enzymes, IgASAP™ Sub1+2 (Genovis), and O-glycosidases, along with EAD fragmentation, a feature of the ZenoTOF 7600 mass spectrometer from Sciex.

Edwige Beng-Louka, Senior scientist, Novartis Pharma AG

×

Edwige Beng-Louka / Profiling and characterizing O-glycosylation in the hinge region of immunoglobulin A by bottom-up mass spectrometry.

Edwige Beng-Louka, Senior scientist,
Novartis Pharma AG

Edwige is working as a Senior Scientist in mass spectrometry at Biomedical Research, NOVARTIS Switzerland. She holds a master’s degree in analytical chemistry from the University of Rennes, France, and has acquired an extensive expertise in the characterization of therapeutic proteins over the last ...

CloseMore